Panoptes Pharma (PP-001 marketing rights in two European countries)

Panoptes Pharma (PP-001 marketing rights in two European countries) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Panoptes Pharma (PP-001 marketing rights in two European countries) General Information

Description

A marketing rights for pre-clinical development molecule in Austria. The asset features marketing rights of PP-001, a small molecule which is currently in preclinical development as potential next generation treatment for several inflammatory eye diseases including non-infectious uveitis in two European countries.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Acquirer
Laboratoires Leurquin Mediolanum
Primary Office
  • Reisnerstraße 34/1
  • Vienna, 1030
  • Austria
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Panoptes Pharma (PP-001 marketing rights in two European countries) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Panoptes Pharma (PP-001 marketing rights in two European countries)‘s full profile, request access.

Request a free trial

Panoptes Pharma (PP-001 marketing rights in two European countries) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Panoptes Pharma (PP-001 marketing rights in two European countries)‘s full profile, request access.

Request a free trial